



ALTERDIAG raised €2M in Seed funding to develop innovative Rapid Diagnostic Tests

Paris, France, January 29, 2025 – ALTERDIAG, a private biotech company specializing in the development of rapid diagnostic tests targeting infectious disease pathogens, announces a €2 million seed funding round from Forepont Capital Partners, a New York-based venture capital firm specializing in healthcare and life sciences.

This fundraising coincides with the signing of a strategic partnership between ALTERDIAG and the Diagnostic Test Innovation and Development Core Facility at the Institut Pasteur in Paris. The collaboration aims to advance research and develop new rapid tests using lateral flow immunochromatography with single-domain antibodies (VHH). This funding will enable ALTERDIAG to launch its first R&D programs and expand its scientific and regulatory teams.

Karine Mignon Godefroy, General Manager of ALTERDIAG, stated : « *Thanks to this successful seed funding round, ALTERDIAG is ideally positioned to become one of the most innovative players in the rapid diagnostics sector. This initial investment will allow us to begin our collaboration with the Institut Pasteur and address unmet medical needs. We are committed to innovating and developing products that will improve patient health.* »

Ismail Kola, Ph.D, Chief Scientific Officer at FOREPONT CAPITAL PARTNERS, added : « *Forepont is proud to support the cutting-edge technological advancements developed by the Institut Pasteur and AlterDiag. We firmly believe in the potential of VHH to overcome the limitations of conventional monoclonal antibodies currently used in rapid diagnostic tests.* »



About AlterDiag :

Founded in 2024 by Dr. Karine Mignon-Godefroy and Mr. Cédric Béchet, AlterDiag aims to become a leading player in the global market for innovative rapid tests. The company develops high-performance, accessible diagnostic tools tailored to the specific needs of patients and healthcare professionals. AlterDiag has already secured initial funding from Forepont Capital Partners, a Franco-American investment fund specializing in financing biotech, medtech, and innovative startups in the healthcare sector.

To learn more : www.alterdiag.com

About Forepont Capital Partners :

[Forepont Capital Partners](http://www.forepont.com) is a healthcare and life science venture capital firm based in New York with a strong presence in Europe. Forepont has developed partnerships with industry leaders, physicians, key opinion leaders, universities, hospitals and pharmaceutical groups, mainly in neurology. Forepont invests in early-stage companies whose science and technology are intended to positively impact the lives of patients. Forepont provides scientific, technological, financial and operational support to improve portfolio company performance, leveraging their talents with its know-how and global ecosystem. To learn more, please visit

www.forepont.com

###

CONTACTS

Press Relation :

Cédric Béchet – COO

Email: pr@alterdiag.com

Tel: +33 7 75 71 75 12